<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(1)</volume><submitter>Cho YE</submitter><pubmed_abstract>Cisplatin is used widely for treatment of a variety of cancer diseases. Recently, however, the use of cisplatin is restricted because of its adverse effects such as hepatotoxicity. There is no study with current proteomics technology to evaluate cisplatin-induced hepatotoxicity, even if some studies have reported on the hepatotoxicity. In this study, proteomic as well as genomic analyses have been used for identification of proteins and genes that respond to cisplatin treatment in rat primary hepatocytes. To investigate the hepatotoxic effects of cisplatin, rat primary hepatocytes were treated with an IC(20) concentration for 24 h. From proteomic analysis based on label-free quantitation strategy, cisplatin induced 76 up-regulated and 19 down-regulated proteins among 325 distinct proteins.</pubmed_abstract><journal>Molecular &amp; cellular proteomics : MCP</journal><pagination>M111.010884</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3270101</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>In-depth identification of pathways related to cisplatin-induced hepatotoxicity through an integrative method based on an informatics-assisted label-free protein quantitation and microarray gene expression approach.</pubmed_title><pmcid>PMC3270101</pmcid><pubmed_authors>Singh TSK</pubmed_authors><pubmed_authors>Baek MC</pubmed_authors><pubmed_authors>Lee MH</pubmed_authors><pubmed_authors>Lee HC</pubmed_authors><pubmed_authors>Lee JE</pubmed_authors><pubmed_authors>Cho YE</pubmed_authors><pubmed_authors>Kim SH</pubmed_authors><pubmed_authors>Chen YJ</pubmed_authors><pubmed_authors>Choi EC</pubmed_authors><pubmed_authors>Moon PG</pubmed_authors></additional><is_claimable>false</is_claimable><name>In-depth identification of pathways related to cisplatin-induced hepatotoxicity through an integrative method based on an informatics-assisted label-free protein quantitation and microarray gene expression approach.</name><description>Cisplatin is used widely for treatment of a variety of cancer diseases. Recently, however, the use of cisplatin is restricted because of its adverse effects such as hepatotoxicity. There is no study with current proteomics technology to evaluate cisplatin-induced hepatotoxicity, even if some studies have reported on the hepatotoxicity. In this study, proteomic as well as genomic analyses have been used for identification of proteins and genes that respond to cisplatin treatment in rat primary hepatocytes. To investigate the hepatotoxic effects of cisplatin, rat primary hepatocytes were treated with an IC(20) concentration for 24 h. From proteomic analysis based on label-free quantitation strategy, cisplatin induced 76 up-regulated and 19 down-regulated proteins among 325 distinct proteins.</description><dates><release>2012-01-01T00:00:00Z</release><publication>2012 Jan</publication><modification>2025-04-26T06:36:07.508Z</modification><creation>2020-11-19T13:24:22Z</creation></dates><accession>S-EPMC3270101</accession><cross_references><pubmed>22023808</pubmed><doi>10.1074/mcp.M111.010884</doi><doi>10.1074/mcp.m111.010884</doi></cross_references></HashMap>